Drug Distributor 13Fs: McKesson, Cencora, Cardinal Health

US pharmaceutical distribution equities form a distinctive defensive-healthcare corner of institutional 13F positioning. McKesson, Cencora (COR, formerly AmerisourceBergen), and Cardinal Health anchor the three-company oligopoly. Specialty drug economics (high-margin biologics distribution), GLP-1 obesity therapy distribution boom, multi-year generic price deflation cycles, and disciplined capital-return frameworks drive distinctive institutional patterns. Reading drug distributor 13F positioning requires understanding the three-company oligopoly framework plus the multi-year specialty-and-GLP-1 cycle dynamics.

The drug distribution business model

Drug distributors face four primary economic drivers:

1. Three-company oligopoly. McKesson, Cencora, and Cardinal Health control approximately 90%+ of US pharmaceutical distribution. The oligopoly structure provides stable competitive dynamics plus disciplined capital allocation.
2. Specialty drug economics. Specialty drug (biologics, oncology, orphan disease) distribution generates higher per-script revenue and margins than traditional generic distribution. Multi-year specialty mix expansion drives revenue trajectory.
3. GLP-1 distribution boom. Multi-year GLP-1 obesity therapy (Ozempic, Wegovy, Mounjaro, Zepbound) distribution drives substantial revenue growth. Multi-year demand trajectory provides multi-year revenue tailwind.
4. Generic deflation cycles. Multi-year generic drug price deflation cycles compress per-script economics on traditional generic distribution. Cycle inflections affect operator margins.

Major US drug distributors

McKesson (MCK)

Largest US pharmaceutical distributor. Diversified across pharmaceutical distribution, medical-surgical solutions, prescription technology solutions, and international operations. Multi-decade dividend growth track record.

Cencora (COR)

Formerly AmerisourceBergen, rebranded 2023. Diversified pharmaceutical distribution plus specialty plus animal health (MWI Veterinary Supply) plus international operations. Multi-year capital deployment plus shareholder returns.

Cardinal Health (CAH)

Diversified pharmaceutical distribution plus medical solutions plus pharmaceutical and specialty services. Multi-year operational restructuring plus capital return discipline.

How institutional managers position around drug distributors

Three patterns:

Pattern 1: Oligopoly-stability concentration

MCK-concentrated active manager positions reflect three-company oligopoly stability plus disciplined operational management.

Pattern 2: GLP-1 boom positioning

All three distributors benefit from GLP-1 distribution boom. Concentrated active manager positions reflect multi-year GLP-1 demand thesis.

Pattern 3: Specialty growth positioning

COR-concentrated active manager positions reflect specialty drug distribution thesis plus animal health diversification.

How to read drug distributor 13F positioning

Three rules:

Rule 1: Identify specialty mix exposure

Each distributor's specialty drug mix determines margin profile.

Rule 2: Watch GLP-1 distribution disclosure

Quarterly GLP-1-related revenue plus broader specialty disclosure drives multi-quarter visibility.

Rule 3: Cross-check generic deflation cycle

Multi-year generic price deflation cycles affect traditional generic distribution economics.

What drug distributor positioning signals

1. Oligopoly-stability conviction. Concentrated MCK positions signal manager view on oligopoly competitive dynamics.
2. GLP-1 boom conviction. Concentrated positions across MCK, COR, CAH signal GLP-1 distribution demand thesis.
3. Specialty growth conviction. Concentrated COR positions signal specialty drug distribution thesis.

For real-time tracking of drug distributor 13F activity, see the institutional signals feed.